Comparative Pharmacology
Head-to-head clinical analysis: INLYTA versus QINLOCK.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INLYTA versus QINLOCK.
INLYTA vs QINLOCK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Axitinib is a tyrosine kinase inhibitor that selectively inhibits vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, and VEGFR-3), which are involved in pathologic angiogenesis, tumor growth, and metastatic progression of cancer.
Ripretinib is a switch-control tyrosine kinase inhibitor that inhibits KIT proto-oncogene receptor tyrosine kinase (KIT) and platelet-derived growth factor receptor alpha (PDGFRA) kinase signaling. It binds to both the switch pocket and the activation loop of KIT and PDGFRA, preventing kinase activation and inhibiting downstream signaling pathways involved in tumor cell proliferation and survival.
5 mg orally twice daily, approximately 12 hours apart, with or without food.
150 mg orally once daily with food, until disease progression or unacceptable toxicity.
None Documented
None Documented
Terminal elimination half-life is approximately 13–17 hours in patients, supporting twice-daily dosing.
Terminal elimination half-life is approximately 15 hours (range 11–20 hours) in patients with advanced GIST. This supports twice-daily dosing.
Primarily hepatic metabolism via CYP3A4 and subsequent biliary-fecal elimination (approximately 61% of dose recovered in feces, 23% in urine as metabolites; <10% excreted unchanged in urine or feces).
Primarily hepatic metabolism, with <1% excreted unchanged in urine. Fecal excretion accounts for approximately 80% of the administered dose, with renal excretion of unchanged drug being minimal (<1%).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor